Applied Casesadvanced

Case: Valuing CSL Limited (CSL)

CSL Limited (CSL) is an ASX-listed global biotechnology and plasma group that reports in US dollars, with total operating revenue of approximately US$14.8 billion and research and development spending of about US$1.4 billion (FY2024, year ended 30 June 2024). A research-intensive drug pipeline holds value a static DCF misses, because management can act as uncertainty resolves rather than commit up front. This case adds the real options embedded in the pipeline to a base DCF of the existing business. It teaches the expand, abandon and delay taxonomy of managerial flexibility, why an option is a right and not an obligation, and the result that most unsettles a DCF intuition, that higher volatility raises option value rather than lowering it. A decision-tree view of staged trials shows where that flexibility lives.

Why it matters

A plain DCF treats a risky drug program as a single forced bet, discounting one expected cash flow at a high rate, which buries the most valuable thing management actually owns, the freedom to wait and see. In reality a pipeline is a chain of choices. Run a small trial, and only if it reads out well do you pour in the big launch spending. That right to expand a winner, walk away from a loser and delay a launch until the science is clearer behaves like a portfolio of call options. Because an option caps the downside at the money already spent while leaving the upside open, more uncertainty makes it worth more, the exact opposite of how risk lowers a DCF. So total value is the steady existing business plus the option value of the pipeline.

Formulas

Total value as base business plus pipeline options

V_{\text{total}} = V_{\text{base DCF}} + \displaystyle\sum_{i} \text{Option value}_i

Value the existing in-market business with a conventional DCF, then add the value of the portfolio of real options in the pipeline, the rights to expand, abandon or delay each program. The options are additive on top of the base, never a substitute for it.

Expansion or launch option payoff

C = \max\!\left(0,\; \text{PV}_{\text{underlying}} - I\right), \qquad C = C\!\left(\text{PV}_{\text{underlying}},\, I,\, \sigma,\, T\right)

At the decision point the right to launch pays the present value of the drug’s cash flows minus the investment cost I, floored at zero, so a failed program is simply abandoned. Before that point its value depends on the underlying PV, the cost I, the volatility of the prospects and the time T available to decide, and it rises with volatility.

Worked examples

Scenario

CSL reported total operating revenue of approximately US$14.8 billion and R&D spending of about US$1.4 billion (FY2024). For illustration only, suppose the existing business is worth US$70 billion by base DCF, and one pipeline drug needs US$2 billion to launch and would then be worth US$3 billion in present value if it succeeds but nothing if it fails, with a 50 percent chance of success. Why does a static DCF understate this drug, and how does the option view change it?

Solution

Every figure except the US$14.8 billion revenue and US$1.4 billion R&D scales is illustrative and exists to show the method. A static expected-value DCF runs the drug as one forced bet, half of three billion plus half of zero, less the two billion outlay, which is a half-billion loss in present value, so the naive model would reject the program outright. The option view recognises that CSL is not forced to spend the two billion now. It can wait, and it will only launch in the world where the present value is three billion, abandoning the failed world at no further cost. The launch payoff is then the maximum of zero and three minus two billion, which is one billion in the good state and zero in the bad, an expected payoff of about half a billion before discounting rather than a loss. That gap is the value of the right to abandon. The lesson lands on volatility. Compare two drugs with the same expected present value but different uncertainty. A low-uncertainty drug whose present value lands near the two billion launch cost on either side is barely worth launching, so its option is thin. A high-uncertainty drug with the same average present value but a far wider spread, a large success value against a near-zero failure, is worth much more, because launching captures the high success states while the firm walks away from the failures at no extra cost. Higher uncertainty raises pipeline option value even when the expected present value is unchanged, the reverse of how risk lowers a plain DCF. The total firm value is the US$70 billion base plus the summed value of these pipeline options.

NoteThe US$70 billion base value, the US$2 billion and US$3 billion drug figures, the 50 percent probability, the volatility and every resulting option and total value are illustrative and serve to show the real-options method, not to state CSL’s actual pipeline value, cost of capital or firm value. Only the US$14.8 billion total revenue and the about US$1.4 billion R&D spending are reported figures.

Common mistakes

✗A drug program with a negative static NPV should always be rejected. A staged program carries the right to abandon after a cheap early trial, so its option value can be positive even when the all-or-nothing expected NPV is negative.
✗Higher volatility lowers the value of a pipeline. For a real option the downside is capped at the money committed while the upside stays open, so more uncertainty raises option value, the opposite of its effect on a plain DCF.
✗The real-option value replaces the discounted-cash-flow value. Total value is the base DCF of the existing business plus the option value of the pipeline. The options are additive, not a substitute for the core valuation.
✗A real option is an obligation to invest in every program. It is a right, not a duty, so management expands only winners, abandons losers and delays launches until uncertainty clears, which is exactly what creates the extra value.

Revision bullets

•CSL is an ASX-listed plasma and biotech group reporting in US dollars, revenue about US$14.8 billion and R&D about US$1.4 billion (FY2024)
•Total value equals the base DCF of the existing business plus the pipeline real options
•The pipeline holds expand, abandon and delay options, rights and not obligations
•A launch option pays the maximum of zero and underlying PV minus investment cost
•Higher volatility raises real-option value, the reverse of its DCF effect
•A decision tree maps the staged trial choices where the flexibility lives

Quick check

Why can a research-intensive firm like CSL be worth more than its base DCF suggests?

In a real-options view of a drug pipeline, an increase in the volatility of a program’s prospects

Connected topics

Decision Trees Risk vs Uncertainty Multi-Stage DCF Real Options Expand/Abandon/Delay

Sources

CSL Limited (2024)
CSL Limited. FY2024 Annual Report, Consolidated Income Statement, year ended 30 June 2024 (reported in US dollars).
Source for the total operating revenue of approximately US$14.8 billion and research and development spending of about US$1.4 billion. All probabilities, cash flows, option values, volatility and firm values in this case are illustrative.
Titman & Martin on real options
Titman, S., & Martin, J. D. Valuation: The Art and Science of Corporate Investment Decisions. Pearson.
Grounds real options and the expand, abandon and delay taxonomy of managerial flexibility used here.
Damodaran on real options
Damodaran, A. Investment Valuation: Tools and Techniques for Determining the Value of Any Asset. Wiley.
Develops the valuation of high-uncertainty firms and the pricing of pipeline real options, including why volatility raises option value.

How to cite this page

Dr. Phil's Quant Lab. (2026). Case: Valuing CSL Limited (CSL). Derivatives Atlas. https://phucnguyenvan.com/concept/sabv-case-csl

← Back to the atlas See in the network →